Success Story: NIW Approval for Research Advancing Computational Drug Discovery and Precision Medicine
Client’s Testimonial:
"I appreciate your help; everything was great."
On July 20th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the Field of Bioinformatics and Computational Chemistry (Approval Notice).
General Field: Bioinformatics and Computational Chemistry
Position at the Time of Case Filing: Research Scientist
Country of Origin: Bulgaria
State of Residence at the Time of Filing: Tennessee
Approval Notice Date: July 20th, 2026
Processing Time: 19 months, 2 days (Premium Processing Requested)
Case Summary:
The petition focused on the client's work developing an advanced biomolecular platform capable of analyzing complex protein structures and the effects of genetic mutations and targeted compounds. By integrating structural biology, bioinformatics, and machine learning, this platform helps researchers better understand molecular behavior and supports the design of targeted therapeutics with greater clinical selectivity and reduced toxicity. We demonstrated that these advances have broad implications for improving treatments for severe systemic diseases while supporting U.S. priorities in biomedical innovation and critical and emerging technologies.
To establish that the client was well positioned to continue advancing this work, North America Immigration Law Group (Chen Immigration Law Associates) presented evidence of both technical expertise and sustained scientific achievement. The client had earned a Ph.D. in Chemistry and Pharmaceutical Sciences and developed computational workflows and structural databases used in kinase research. The record also included 9 peer-reviewed journal articles, a first-authored book chapter, and a patent application. These accomplishments demonstrated an ongoing commitment to developing computational tools that enable more efficient drug discovery.
The petition further showed that the client's research had become an important resource for the scientific community. At the time of filing, the published work had received 881 citations, including two papers ranked among the top 1% most cited Biology & Biochemistry publications for their publication years. Researchers investigating targeted drug development and advanced computational pharmacology had incorporated the client's databases and analytical methods into their own studies, illustrating that the work had become a vital part of the infrastructure supporting continued advances in precision medicine.
USCIS approved the NIW petition on July 20th, 2026, following a Premium Processing upgrade submitted on May 14th, 2026. We are proud that our firm could assist in presenting a petition demonstrating how the client's expertise in bioinformatics and computational chemistry contributed to the development of more precise therapeutic strategies, advanced computational drug discovery, and supported future biomedical innovation in the United States.